| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/22/2006 | CN1245987C Stability enhanced erigeron breviscapus injection and its preparation method |
| 03/22/2006 | CN1245984C Preparation for prevention and/or treatment of vascular disorders |
| 03/22/2006 | CN1245974C Carvedilol |
| 03/22/2006 | CN1245973C Use of biochemical material for preparing medicine for preventing and treating disease caused by smooth muscle cell contraction in human organ |
| 03/22/2006 | CN1245971C Tea poly phenol soft capsule and its preparation process |
| 03/22/2006 | CN1245970C Tanshinone 11A used in preparing medicine for preventing and treating atherosclerosis |
| 03/22/2006 | CN1245963C Medicinal composition including bradycardiac substances and ist use |
| 03/22/2006 | CN1245956C Method for producing oral administration delay-control release verapamil hydrochloride micro balls |
| 03/21/2006 | US7015238 Crystalline organic acid salt of amlodipine |
| 03/21/2006 | US7015237 Pyridine matrix metalloproteinase inhibitors |
| 03/21/2006 | US7015232 Stablizer retards cyclization and discoloration of quinapril |
| 03/21/2006 | US7015231 such as (3Z)-3-[(1-methyl-1H-indol-3-yl)methylene]-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one; tyrosine kinase inhibitors; for treatment of tumor growth, restenosis, atherosclerosis, pain and thrombosis |
| 03/21/2006 | US7015229 An antagonist of a corticotropin releasing factor (CRF) receptor, treating central nervous system disorders or anxiety disorders, depression and stress |
| 03/21/2006 | US7015220 enzyme inhibitors used as modulators of tyrosine kinase signal transduction and/or as antiproliferative agents; prophylaxis of vision defects, cancer, atherosclerosis, restenosis, metabolic disorders or autoimmune diseases |
| 03/21/2006 | US7015217 Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 03/21/2006 | US7015216 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
| 03/21/2006 | US7015200 Carbohydrates conjugated to optionally protected 4-hydroxybutyric acid; enhance the uptake of the drug and allows effective drug delivery to treat GHB-treatable disorders such as sleep disorders or drug withdrawal |
| 03/21/2006 | US7015015 Nucleotide sequences coding polypeptide for use in treatment of diabetes, epilepsy, depression, ischemia and muscle disorders |
| 03/21/2006 | US7014838 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 03/21/2006 | CA2399358C Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 03/21/2006 | CA2315220C Integrin receptor antagonists |
| 03/21/2006 | CA2270887C Methods and compositions for inhibition of angiogenesis |
| 03/21/2006 | CA2267251C Novel phenoxyethylamine derivatives, method of preparation, application as medicine and pharmaceutical compositions containing same |
| 03/21/2006 | CA2263983C Cyclic amine derivatives for inhibiting blood platelet aggregation |
| 03/21/2006 | CA2238816C N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists |
| 03/21/2006 | CA2178949C Morpholine and thiomorpholine tachykinin receptor antagonists |
| 03/21/2006 | CA2139112C Novel nicotinic acid esters |
| 03/21/2006 | CA2129771C Phenylalkanolamine derivatives |
| 03/21/2006 | CA2072416C Cyclopropenone derivatives |
| 03/17/2006 | CA2477867A1 Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
| 03/16/2006 | WO2006029371A2 Neuromedin u 2 receptor agonists and uses thereof |
| 03/16/2006 | WO2006029349A1 Combination of organic compounds |
| 03/16/2006 | WO2006028904A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | WO2006028875A1 Phenanthridine carbonyl phenols as cytokine modulators |
| 03/16/2006 | WO2006028590A1 1,1,2,2-tetra (hetero) arylethanes or 1,1,2-tri (hetero) aryl-2-heterocyclylethanes as potassium channel inhibitors |
| 03/16/2006 | WO2006028239A1 Carbamoyl-substituted spiro derivative |
| 03/16/2006 | WO2006028122A1 Agent for preventing and ameliorating obesity |
| 03/16/2006 | WO2006027366A1 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
| 03/16/2006 | WO2006027142A1 Substituted phenylaminothiazoles and use thereof |
| 03/16/2006 | WO2006027130A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds |
| 03/16/2006 | WO2006027052A2 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 03/16/2006 | WO2006017054A3 Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| 03/16/2006 | WO2006016363A3 Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions |
| 03/16/2006 | WO2006002763A3 Substituted tetrahydroisochinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drags |
| 03/16/2006 | WO2005103076A3 Erythropoietin protein variants |
| 03/16/2006 | WO2005100349A3 Polycyclic pyridines as potassium ion channel modulators |
| 03/16/2006 | WO2005070463A3 Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| 03/16/2006 | WO2005063745A3 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 03/16/2006 | US20060058552 Solid preferably with an aspect ratio of 1 to 4 and a solubility in water at room temperature of at least 425 mg/ml. |
| 03/16/2006 | US20060058533 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 03/16/2006 | US20060058389 Novel compounds that inhibit factor xa activity |
| 03/16/2006 | US20060058376 Composition having autonomic nerve modulating activity and method of use thereof |
| 03/16/2006 | US20060058374 Urotensin II receptor agents |
| 03/16/2006 | US20060058372 N-Benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them |
| 03/16/2006 | US20060058371 Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease |
| 03/16/2006 | US20060058366 Jnk inhibitor |
| 03/16/2006 | US20060058355 Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker |
| 03/16/2006 | US20060058349 Piperidinetriol derivatives as inhibitors of glycosyceramid synthase |
| 03/16/2006 | US20060058346 Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions |
| 03/16/2006 | US20060058342 For therapy and prophylaxis of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis |
| 03/16/2006 | US20060058329 Pyrazole inhibitors of the transforming growth factor |
| 03/16/2006 | US20060058320 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives |
| 03/16/2006 | US20060058304 Azaindole kinase inhibitors |
| 03/16/2006 | US20060058302 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases; example compound: 2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(2-ethyl-hexyl)-benzamide |
| 03/16/2006 | US20060058294 Carboxamidine derivatives and their use in the treatment of vascular diseases |
| 03/16/2006 | US20060058288 Severe sepsis preventive therapeutic agent |
| 03/16/2006 | US20060058267 Pharmaceutical compositions comprising a NOS inhibitor |
| 03/16/2006 | US20060058258 Gene transcription and ionizing radiation: methods and compositions |
| 03/16/2006 | US20060058242 Dipeptide derivatives |
| 03/16/2006 | US20060057714 Vector |
| 03/16/2006 | US20060057663 Novel g protein-coupled receptor protein and dna thereof |
| 03/16/2006 | US20060057648 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) |
| 03/16/2006 | US20060057218 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 03/16/2006 | US20060057146 Selective targeting of tumor vasculature using antibody molecules |
| 03/16/2006 | US20060057117 Vascular endothelial growth factor 2 |
| 03/16/2006 | DE102004038328A1 Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten New uses of 2-phenyl-substituted derivatives imidazotriazinone |
| 03/16/2006 | DE102004035808A1 Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen Ammonium salts and ammonium salt Mineralsalzchlatrate as transport and active form for pharmaceutical and medical-phase transfer agent for chemical applications |
| 03/16/2006 | CA2580132A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds |
| 03/16/2006 | CA2579621A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 03/16/2006 | CA2579303A1 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
| 03/16/2006 | CA2579204A1 Carbamoyl-substituted spiro derivative |
| 03/16/2006 | CA2578958A1 Acetylated starch or starch succinate for treatment of obesity or diabetes |
| 03/16/2006 | CA2578933A1 Phenanthridine carbonyl phenols as cytokine modulators |
| 03/16/2006 | CA2578739A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | CA2578290A1 Combination of organic compounds |
| 03/16/2006 | CA2577819A1 Methods for assessing atherosclerosis |
| 03/16/2006 | CA2577408A1 Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators |
| 03/15/2006 | EP1634953A2 Platelet-activating factor acethylhydrolase |
| 03/15/2006 | EP1634880A2 Processes for preparing losartan and losartan potassium |
| 03/15/2006 | EP1634876A2 Heterocyclic compounds for the treatment of hyperlipidemia agents |
| 03/15/2006 | EP1634594A1 Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators |
| 03/15/2006 | EP1634498A2 Exo-S-mecamylamine formulation |
| 03/15/2006 | EP1633883A1 Method for assaying lkb1 phosphorylation activity |
| 03/15/2006 | EP1633747A1 Tetrahydroisoquinoline derivatives as ppar-a activators |
| 03/15/2006 | EP1633738A2 Novel indole derivatives, method of preparing same in the form of medicaments, pharmaceutical compositions and, in particular, kdr inhibitors |
| 03/15/2006 | EP1633735A1 Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics |
| 03/15/2006 | EP1633721A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives |
| 03/15/2006 | EP1633718A2 COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| 03/15/2006 | EP1633383A2 Use of erythropoietin in stroke recovery |
| 03/15/2006 | EP1633371A1 Method of treating atrial fibrillation or atrial flutter |